188 related articles for article (PubMed ID: 37126315)
1. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
3. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
4. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
[TBL] [Abstract][Full Text] [Related]
5. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
[TBL] [Abstract][Full Text] [Related]
6. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
[TBL] [Abstract][Full Text] [Related]
7. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the Detection and Care of Heterozygous Familial Hypercholesterolemia in Primary Care: Cost-Effectiveness and Return on Investment.
Marquina C; Morton J; Brett T; Lloyd M; Radford J; Heal C; Hespe C; Gill G; Sullivan D; Zomer E; Li I; Pang J; Watts GF; Ademi Z
Circ Genom Precis Med; 2023 Jun; 16(3):267-274. PubMed ID: 37042242
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
[TBL] [Abstract][Full Text] [Related]
10. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
Chen CX; Hay JW
Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
16. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
19. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]